About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Phase I Combination Ixabepilone + Cisplatin | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 1NCT00832117

Phase I Combination Ixabepilone + Cisplatin

The purpose of this study is to determine the highest dose of ixabepilone that can be given safely with cisplatin without causing severe or life-threatening side effects and for some patients with non...

Lead sponsor: R-Pharm•3 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

R-Pharm

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Escalation Phase Subjects: Primary solid tumor not curable by local measures such as surgery, radiation
•Men and women age ≥ 18
•Exclusion:
•More than 2 prior chemotherapy containing regimens for metastatic disease
•No prior exposure to cisplatin or ixabepilone
•Expansion Phase Subjects: Advanced Non-small cell lung cancer
•Men and women age ≥ 18
•Exclusion:
•No prior chemotherapy-containing regimen for metastatic disease
•No prior exposure to cisplatin or ixabepilone

Related studies

RECRUITINGPhase 2

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

NCT06364917 · Non Small Cell Lung Cancer

RECRUITINGPhase 3

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137 · Non Small Cell Lung Cancer

Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer

NCT07563205 · Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, and more

RECRUITINGPhase 1/2

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

NCT06814496 · Melanoma, Medullary Thyroid Cancer, and more

RECRUITINGPhase 3

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

NCT05671510 · Non Small Cell Lung Cancer

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 28, 2020Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment30

Start dateMay 2009

Last updatedOct 28, 2020

Condition

Non Small Cell Lung Cancer

Locations shown

Georgetown University Medical Center

Washington D.C., District of Columbia

The Cancer Institute Of New Jersey

New Brunswick, New Jersey

Penn State Milton S. Hershey Medical Center

Hershey, Pennsylvania

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 28, 2020Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions